Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer

被引：0
作者：
O. Köstek
N. C. Demircan
A. Gökyer
A. Küçükarda
B. S. Sunal
M. B. Hacıoğlu
H. Eslame
S. Solak
E. Yılmaz
S. Uzunoğlu
N. Tunçbilek
İ. Çiçin
B. Erdoğan
机构：
[1] Trakya University School of Medicine,Division of Medical Oncology, Department of Internal Medicine
[2] Trakya University School of Medicine,Department of Radiology
[3] Trakya University School of Medicine,undefined
来源：
Clinical and Translational Oncology | 2019年 / 21卷
关键词：
Skeletal muscle mass; Anti-EGFR treatment; Metastatic colorectal cancer; Prognosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1510 / 1517
页数：7
相关论文
共 50 条
  • [21] Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers
    A Harlé
    J Salleron
    G Perkins
    C Pilati
    H Blons
    P Laurent-Puig
    J L Merlin
    British Journal of Cancer, 2015, 113 : 680 - 685
  • [22] First-Line Therapy in Metastatic, RAS Wild-Type, Left-Sided Colorectal Cancer: Should Everyone Receive Anti-EGFR Therapy?
    Airoldi, Marco
    Bartolini, Michela
    Fazio, Roberta
    Farinatti, Sara
    Dapra, Valentina
    Santoro, Armando
    Puccini, Alberto
    CURRENT ONCOLOGY REPORTS, 2024, 26 (11) : 1489 - 1501
  • [23] Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis
    Palmieri, Lola-Jade
    Buchler, Tomas
    Meyer, Antoine
    Veskrnova, Veronika
    Fiala, Ondrej
    Brabec, Petr
    Baranova, Jana
    Coriat, Romain
    CANCERS, 2022, 14 (06)
  • [24] Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients
    Kurk, Sophie
    Peeters, Petra
    Stellato, Rebecca
    Dorresteijn, B.
    de Jong, Pim
    Jourdan, Marion
    Creemers, Geert-Jan
    Erdkamp, Frans
    de Jongh, Felix
    Kint, Peter
    Simkens, Lieke
    Tanis, Bea
    Tjin-A-Ton, Manuel
    Van Der Velden, Ankie
    Punt, Cornelis
    Koopman, Miriam
    May, Anne
    JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2019, 10 (04) : 803 - 813
  • [25] Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer
    Dalyong Kim
    Sun Young Kim
    Ji Sung Lee
    Yong Sang Hong
    Jeong Eun Kim
    Kyu-pyo Kim
    Jihun Kim
    Se Jin Jang
    Young-Kwang Yoon
    Tae Won Kim
    BMC Gastroenterology, 17
  • [26] Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer
    Grasselli, J.
    Elez, E.
    Caratu, G.
    Matito, J.
    Santos, C.
    Macarulla, T.
    Vidal, J.
    Garcia, M.
    Vieitez, J. M.
    Paez, D.
    Falco, E.
    Lopez Lopez, C.
    Aranda, E.
    Jones, F.
    Sikri, V.
    Nuciforo, P.
    Fasani, R.
    Tabernero, J.
    Montagut, C.
    Azuara, D.
    Dienstmann, R.
    Salazar, R.
    Vivancos, A.
    ANNALS OF ONCOLOGY, 2017, 28 (06) : 1294 - 1301
  • [27] Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies
    Rachiglio, Anna Maria
    Forgione, Laura
    Pasquale, Raffaella
    Barone, Carlo Antonio
    Maiello, Evaristo
    Antonuzzo, Lorenzo
    Cassata, Antonino
    Tonini, Giuseppe
    Bordonaro, Roberto
    Rosati, Gerardo
    Zaniboni, Alberto
    Lonardi, Sara
    Ferrari, Daris
    Frassineti, Giovanni Luca
    Tamberi, Stefano
    Pisconti, Salvatore
    Di Fabio, Francesca
    Roma, Cristin
    Orlandi, Armando
    Latiano, Tiziana
    Damato, Angela
    Tortora, Giampaolo
    Pinto, Carmine
    Normanno, Nicola
    CANCERS, 2022, 14 (04)
  • [28] Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
    Rowland, A.
    Dias, M. M.
    Wiese, M. D.
    Kichenadasse, G.
    McKinnon, R. A.
    Karapetis, C. S.
    Sorich, M. J.
    BRITISH JOURNAL OF CANCER, 2015, 112 (12) : 1888 - 1894
  • [29] Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
    A Rowland
    M M Dias
    M D Wiese
    G Kichenadasse
    R A McKinnon
    C S Karapetis
    M J Sorich
    British Journal of Cancer, 2015, 112 : 1888 - 1894
  • [30] Cetuximab Plus Various Chemotherapy Regimens for Patients with KRAS Wild-Type Metastatic Colorectal Cancer
    Azadeh, Payam
    Mortazavi, Nafiseh
    Tahmasebi, Arezoo
    Kamal, Farnaz Hosseini
    Novin, Kambiz
    CHEMOTHERAPY, 2015, 61 (01) : 51 - 56
12345